Veterinary and Comparative Oncology · 2010 · 44 citations · 18 references
MedicineOncologyPharmacologyCancer Drug Toxicity ManagementChemotherapyOncology PharmacotherapyChemotherapy In Hematologic MalignanciesChemotherapy In Veterinary SpeciesChemotherapy Toxicity ManagementToxicity ManagementVeterinary ChemotherapyAnthracycline-based ChemotherapyAnticancer ChemotherapyAntineoplastic Drug TherapyCanine LymphomaChemotherapy Administration In LymphomaCyclophosphamide-based TherapyDoxorubicin-based TherapyLymphoma Chemotherapy
Median survival times (STs) for doxorubicin-treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi-agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable level of toxicity. Thirty-two dogs with stage III-V multicentric lymphoma were treated with doxorubicin every 3 weeks for five total cycles and prednisone at a tapering dose for the first 4 weeks. Dogs were randomized to receive either cyclophosphamide or placebo concurrently. Seventeen dogs received doxorubicin and placebo, while 15 dogs received doxorubicin and cyclophosphamide. Response, toxicity, progression-free interval (PFI) and ST were evaluated. The combination of doxorubicin and cyclophosphamide was well tolerated, causing no increase in adverse events over doxorubicin alone. Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST.
18
Adriamycin cardiomyopathy—risk factors
Robert A. Minow, Robert S. Benjamin, Elisa T. Lee et al. · Cancer · 1977 · 253 citations · Full text
Medicine, Cardiology, Pharmacology +17